AVXL Jan 2025 8.000 put
| Previous close | 3.4000 |
| Open | 3.4000 |
| Bid | 2.7000 |
| Ask | 3.9000 |
| Strike | 8.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.4000 - 3.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.7k |
Simply Wall St.Anavex Life Sciences (NASDAQ:AVXL) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
ZacksAnavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GlobeNewswireAnavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Of
